MIRA: SEC Form 8-K filed by MIRA Pharmaceuticals Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for MIRA
Across the 16 sessions after earlier MIRA headlines, the stock closed higher 9 times and lower 7 times, with a median move of 3.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | MIRA | SPY |
|---|---|---|---|
| Oct 22, 2026 | MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study | -7.8% | -1.2% |
| Sep 17, 2026 | MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review | +5.5% | +1.1% |
| Aug 6, 2026 | MIRA Reports Positive 7-Day Dog Study Results for SKNY-1 | +3.1% | -0.2% |
| Jul 30, 2026 | MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies | -3.0% | +1.7% |
| Jul 10, 2026 | MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain | +0.5% | +0.4% |
| Jul 6, 2026 | MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction | +1.1% | +0.9% |
Quantisnow market dataNASDAQ
MIRA
MIRA Pharmaceuticals Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2023
Get push alerts for MIRA
Full MIRA profile on Quantisnow Follow MIRA and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time